<- Back to Insights
February 13, 2024
23andMe’s Fall From $6 Billion to Nearly $0
Summary
23andMe, once valued at $6 billion, now risks Nasdaq delisting with valuation down 98%, under $1 stock; CEO Wojcicki's billions lost; staff reduced 25% via layoffs, subsidiary sale; company unprofitable, may exhaust cash by 2025.
Explore Related Topics